Edition:
United Kingdom

Valeritas Holdings Inc (VLRX.OQ)

VLRX.OQ on NASDAQ Stock Exchange Capital Market

1.17USD
15 Oct 2018
Change (% chg)

$-0.19 (-13.97%)
Prev Close
$1.36
Open
$1.24
Day's High
$1.27
Day's Low
$1.15
Volume
152,843
Avg. Vol
133,926
52-wk High
$6.79
52-wk Low
$0.78

Summary

Name Age Since Current Position

Peter Devlin

50 2017 Independent Chairman of the Board

John Timberlake

53 2016 President, Chief Executive Officer, Director

Erick Lucera

50 2016 Chief Financial Officer, Executive Vice President

Geoffrey Jenkins

66 2009 Executive Vice President - Manufacturing, Operations and Research & Development

Mark Conley

56 2016 Vice President, Corporate Controller, Treasurer

Hokan Lars Ojert

2016 Vice President - Sales

Scott Huie

53 2016 Vice President - Regulatory Affairs/Quality Assurance and Compliance

Chris Gregory

2013 Vice President - Research & Development

Matthew Nguyen

48 2016 Chief Commercial Officer

Joseph Saldanha

53 2018 Chief Business Officer

Luke Duster

43 2016 Director

Rodney Altman

55 2016 Independent Director

Katherine Crothall

69 2016 Independent Director

Joseph Mandato

73 2016 Independent Director

Brian Roberts

47 2016 Independent Director

Greg Chodaczek

2018 IR Contact Officer

Biographies

Name Description

Peter Devlin

Mr. Peter Devlin is Independent Chairman of the Board of the Company. He has served as a member of our board of directors since April 2016. Since September 2014, Mr. Devlin has served as a consultant for various life sciences and investment companies. From August 2009 to September 2014, Mr. Devlin was the Chief Commercial Officer at Insulet Corporation, a tubeless insulin pump technology company. Mr. Devlin held several leadership roles at Abbott Laboratories, Inc. From February 2008 to July 2009, he served as Divisional Vice President of Abbott’s Global Strategic Marketing in the diabetes care unit, prior to which he served as General Manager, Hospital & Government in the diabetes care unit from December 2006 to February 2008, and prior to which he served as Director of Abbott’s Canadian diabetes unit from September 2003 to December 2006. Mr. Devlin received his Bachelor of Science degree from the University of Massachusetts. Mr. Devlin is qualified to serve as a director because of his extensive business experience in the field of diabetes.

John Timberlake

Mr. John Edward Timberlake is President, Chief Executive Officer, Director of the Company. He has served as our Chief Executive Officer, President and a member of our Board of Directors since February 2016, prior to which he served as President and Chief Commercial Officer since August 2008. Before becoming Chief Executive Officer and President and Chief Commercial Officer, Mr. Timberlake was a General Manager with our company from September 2006 to August 2008. Prior to joining Valeritas, Mr. Timberlake held positions of increasing responsibility from 1991 to 2006 at Sanofi-Aventis (now Sanofi), with his last role as Vice President of Diabetes Marketing, where he was responsible for the diabetes franchise, including the brands Lantus, Apidra and Amaryl. Prior to Sanofi, Mr. Timberlake was a manager with Deloitte & Touche LLP, from 1986 to 1991, and was both a Certified Management Accountant and a Certified Public Accountant. He earned a B.S. in Accounting at Northwest Missouri State University, an M.S. in Management from Purdue University and an M.B.A. from NEOMA Business School (f/k/a E.S.C. Rouen) in France. Mr. Timberlake is qualified to serve as a director because of his role with us, and his extensive operational knowledge of, and executive level management experience in, the biopharmaceutical and medical technology industries.

Erick Lucera

Mr. Erick J. Lucera serves as Chief Financial Officer, Executive Vice President of the Company. In addition Mr. Lucera has served on the Board of Directors for AIT Therapeutics since August 2017. From April 2015 to August 2016, Mr. Lucera served as the Chief Financial Officer, Treasurer and Secretary of Viventia Bio Inc., a late-stage oncology company. From December 2012 to April 2015, he served as Vice President, Corporate Development at Aratana Therapeutics, Inc., a specialty pharmaceutical company focused on companion animals. He served as Vice President, Corporate Development at Sunshine Heart, Inc. a medical device company from March 2012 to December 2012. Mr. Lucera served as Vice President, Healthcare Analyst at Eaton Vance Management, a global asset manager, from February 2008 to November 2011. Mr. Lucera also held various positions at Intrepid Capital Partners, Independence Investment Associates, LLC and Price Waterhouse & Co. from 1990 to 2008. Mr. Lucera earned a C.P.H. from Harvard University in 2001, an M.S.F. from Boston College in 1999, an M.B.A. from Indiana University in 1995 and a Bachelor’s Degree in Accounting from The University of Delaware in 1990. Mr. Lucera currently holds a CFA designation. Mr. Lucera previously held CMA and CPA designations, both of which are expired.

Geoffrey Jenkins

Mr. Geoffrey Jenkins is Executive Vice President, Manufacturing, Operations and Research & Development of the Company, since April 2009. He was Vice President of Worldwide Operations for Inverness Medical, a healthcare technology company, from 2005 to 2009. From 2000 to 2005, he was President and Founding Partner of UV-Solutions, LLC, a healthcare technology company, and from 1997 to 1999 he was Chief Operating Officer of MDI Instruments, Inc., a healthcare technology company. Mr. Jenkins was also Corporate Vice President of Operations of MediSense, Inc. from 1991 to 1997. Prior to becoming Corporate Vice President of Operations, he held various other positions in Operations and Engineering Management with MediSense from 1984 to 1991. Mr. Jenkins earned a B.A. and a B.S. from Clarkson University.

Mark Conley

Mr. Mark Conley is Vice President, Corporate Controller, Treasurer of the Company. Mr. Conley has served as our Vice President, Corporate Controller and Treasurer since February 2016, prior to which he served as our Director of Financial Planning & Analysis since joining Valeritas in August 2012. Mr. Conley was Global Finance Director of the radiation instrumentation business at Thermo Fisher Scientific from 2007 to 2012. In addition, he served at Iron Mountain, Inc. as Vice President, Financial Planning & Analysis from 2005 to June 2007 and Division Controller from 1998 to 2004, as Chief Financial Officer and Controller at HoltraChem Group from 1996 to 1998 and in successive financial leadership roles including Operations Controller at Haemonetics Corporation from 1991 to 1996. Mr. Conley earned a B.S. in Accounting from Oklahoma State University, an M.B.A. from Bryant College, and is a Certified Public Accountant.

Hokan Lars Ojert

Mr. Hokan Lars Ojert is Vice President - Sales of the Company. Hokan has over 18 years of diabetes sales and marketing experience, most recently with Sanofi and its predecessor companies. During his time at Sanofi, Hokan held numerous leadership positions within sales and marketing. His career has afforded him the experience of launching, selling and marketing products such as Amaryl®, Apidra®, Lantus®, and the OptiClik® and SoloSTAR® pen technologies. He was the U.S. marketing lead on the commercialization of the OptiClik® pen and involved with the pre-market development of the SoloSTAR® pen technology. Along with Hokan's vast sales and marketing experience within the diabetes arena, he also brings significant recruiting and hiring capabilities to our organization. Hokan led a sales-force scale-up initiative within the diabetes sales division in the Southeast United States. Hokan is a graduate of the University of Scranton, where he earned a Bachelor of Science degree in management.

Scott Huie

Mr. Scott A. Huie is Vice President - Regulatory Affairs/Quality Assurance and Compliance of the Company. Mr. Huie joined Valeritas in 2002. He has over 30 years’ experience in medical device, pharmaceutical and combination products and has held roles in product/process development, operations, regulatory and quality. Scott was previously vice president, operations at Fusion Medical Technologies, which was acquired by Baxter Healthcare Corporation. He has also worked at Aradigm, Cygnus Therapeutic Systems, Ciba-Geigy and 3M Company. Scott received his Bachelor of Science in chemical engineering from Rensselaer Polytechnic Institute.

Chris Gregory

Mr. Chris Gregory, Ph.D., is Vice President - Research & Development of the Company. He has been developing disposable and durable medical devices since 1986. Prior to joining Valeritas, Chris was director of U.S. research and development for ConvaTec Inc., a disposable medical device company that was originally a division of Bristol-Myers Squibb. At ConvaTec, he was responsible for R&D and maintenance for product lines worth $700 million in annual revenue. Before ConvaTec, Chris was group head for medical devices at Sarnoff Corporation, formally the R&D center for RCA Corp. He also held engineering positions in medical device development at Galileo Electro-Optics and Heraeus LaserSonics. Chris earned a Bachelor of Science and Master of Science from Brown University and a Ph.D. in engineering from Rutgers University.

Matthew Nguyen

Mr. Matthew Nguyen, Pharm.D., is Chief Commercial Officer of the Company. He served as our Sr. Vice President, Commercial from February 2016 to December 2016 and as our Vice President for Integrated Healthcare Management since joining Valeritas in September 2006. Mr. Nguyen was a New Business Development Director for Janssen, LP, a division of Johnson & Johnson, from 2005 to 2006. He served as head of health economics research for metabolism, new product marketing, and head of analytics and commercial effectiveness for the CNS business unit at Sanofi from 2000 to 2005. Mr. Nguyen earned a B.S. in Pharmacy and a Doctor of Pharmacy from the Philadelphia College of Pharmacy and Science. He also completed a Fellowship in Health Economics and Outcomes Research in conjunction with Thomas Jefferson University Hospital and Janssen Pharmaceutical, Inc. and earned an M.B.A. from Rutgers University in New Jersey.

Joseph Saldanha

Mr. Joseph Saldanha is Chief Business Officer of the Company. From April 2016 to July 2017, Mr. Saldanha served as Vice President, Marketing and Business Development of MannKind Corporation. From January 2012 to May 2015, Mr. Saldanha was the General Manager, JULPHAR Diabetes for Gulf Pharmaceutical Industries. Mr. Saldanha has also worked on the Aventis-Pfizer partnership for Exubera and for Sanofi and its predecessors from 2001 to 2008, launching Actonel for osteoporosis in the U.S., and for Lantus in international markets from Paris. Prior to that, from 2008 to 2010, Mr. Saldanha worked in business development at Johnson and Johnson Diabetes, where he helped bring both LifeScan for self-monitoring blood glucose and Animas for insulin pumps to the market. Mr. Saldanha also worked in the United Arab Emirates in a general management role with responsibility for insulin API, diabetes orals and injectables, and distribution of Dexcom CGM for the Middle-Eastern markets from 2012 to 2015. Mr. Saldanha earned a Bachelor of Science degree from Drexel University and a Master of Science degree from the University of Pennsylvania, both in Philadelphia.

Luke Duster

Mr. Luke C. Duster is Director of the Company. Since 2009, Mr. Düster served as managing director at Capital Royalty Group, a healthcare-focused investment firm. Mr. Düster was at Harris Williams & Co., an investment firm, from 2004 to 2009, where he served as Vice President. Mr. Düster also held investment banking roles at the Wallach Company, a regional investment banking boutique, from 2000 to 2002, and at the Nord Companies, a healthcare advisory firm, from 1998 to 2000. Mr. Düster received his B.S. summa cum laude from the University of Colorado at Boulder and an M.B.A. with honors from the Wharton School at the University of Pennsylvania. Mr. Düster is qualified to serve as a director because of his significant experience working with companies backed by private equity investors, particularly in the healthcare industry, as well as his experience with healthcare investing.

Rodney Altman

Dr. Rodney D. Altman, M.D., is Independent Director of the Company. He has served as a member of our board of directors since April 2016. Since June 2016, Dr. Altman has been a member of the board of directors of Milestone Pharmaceuticals and Thrasos Pharmaceuticals in his capacity as an advisor to Business Development Bank of Canada. Since 2011, he has been an Advisor and beginning in March 2016 he has been a Managing Director at Spindletop Capital, a private equity and venture capital firm. Prior to joining Spindletop Capital, he was Regional Medical Director at TeamHealth, an American hospital staffing firm. Dr. Altman was a senior partner at a venture capital firm, CMEA Capital, LLC, from 2006 to 2011, where he built and managed the firm’s medical device practice. Dr. Altman has also held investing roles at other venture funds including Aphelion Capital, LLC, Piper Jaffray Ventures, and TVM Techno Venture Management. Dr. Altman received his medical degree from McGill University and an M.B.A. with honors from the University of Chicago, Booth School of Business. Dr. Altman is qualified to serve as a director because of his extensive clinical and venture capital experience.

Katherine Crothall

Dr. Katherine D. Crothall, Ph.D., is Independent Director of the Company. Since 2010, Dr. Crothall has served as President, CEO and Chairman of the Board of Aspire Bariatrics, a company committed to providing safe and effective treatments for obesity to patients worldwide. Dr. Crothall was a Principal at Liberty Venture Partners, a venture capital firm, from 2006 until November 2010. Dr. Crothall was Founder, President and CEO of Animas Corporation, a manufacturer of insulin infusion pumps, from its inception to its acquisition by Johnson & Johnson Corporation in 2006. Dr. Crothall was also the Founder, President and CEO of two other medical device companies, Luxar Corporation ,which was sold to ESC Medical, and Laakmann Electro-Optics, which was sold to Johnson & Johnson. Dr. Crothall continued running Laakmann Electro-Optics for five years post-acquisition. Dr. Crothall received her B.S. from the University of Pennsylvania and her Ph.D. from the University of Southern California, both in Electrical Engineering. She holds over twenty patents and is the recipient of the Ernst & Young Entrepreneur of the Year Award and the Greater Philadelphia Raymond Rafferty Entrepreneurial Excellence Award. Dr. Crothall is a director of Adhezion BioMedical and Xanitos, Inc. She also sits on the Board of Overseers of the School of Engineering and Applied Sciences at the University of Pennsylvania. Dr. Crothall is qualified to serve as a director because of her extensive clinical and business experience, specifically in the healthcare industry.

Joseph Mandato

Dr. Joseph Mandato, Ph.D., D.M. is Independent Director of the Company. Since March 2003, Dr. Mandato has served as a managing director of DeNovo Ventures, a venture capital firm focused on life sciences. Prior to DeNovo Ventures, Dr. Mandato held top leadership positions at Ioptex, Confer Software, Gynecare and Origin Medsystems. Dr. Mandato also served as a member of the Board of Directors of AxoGen Corporation from February 2006 until its merger with and into AxoGen, Inc. in September 2011, and then served on the Board of AxoGen, Inc. until September 2016. Dr. Mandato served as a member of the Board of Directors of Hansen Medical, Inc. from August 2006 until February 2012. Dr. Mandato received a doctorate in management from Case Western Reserve University, and now serves on its Board of Trustees. Dr. Mandato also holds the Carlo Rossi Chair in Entrepreneurship and Management at the University of San Francisco, is a Lecturer at Stanford University and has served as a Fellow in the Harvard University Advanced Leadership Initiative. Additionally, Dr. Mandato currently serves on the board of Save the Children. Dr. Mandato is qualified to serve as a director because of his extensive work in the healthcare industry and his venture capital experience.

Brian Roberts

Mr. Brian K. Roberts, CPA., is Independent Director of the Company. He has served as a member of our board of directors since July 2016. Mr. Roberts currently serves as chief financial officer of Tarveda Therapeutics and serves as a member of the board of directors and audit chairman of ViewRay. From January 2015 to September 2016, Mr. Roberts served as the Chief Operating and Financial Officer of Avedro, a corneal cross-linking science company. From January 2009 through December 2014, he served as Chief Financial Officer for Insulet Corporation, a tubeless insulin pump technology company. From August 2007 to December 2008, Mr. Roberts served as Chief Financial Officer of Jingle Networks, a provider of advertising and technology solutions for voice and mobile business search. Mr. Roberts is currently a member of the board of directors of ViewRay, Inc. and serves as chair of its audit committee. Mr. Roberts received his Bachelor of Science in Accounting and Finance degree from Boston College. Mr. Roberts is qualified to serve as a director because of his extensive business experience and financial and accounting insight.

Greg Chodaczek